A Phase I, Double-blind, Randomised, Single-dose, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD204 and Bevacizumab (Avastin) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Bevacizumab (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Prestige BioPharma
- 10 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.
- 12 Dec 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
- 23 Sep 2018 Status changed from not yet recruiting to recruiting.